IP Group Plc Q2 2026 Earnings Recap

IP Group’s shares rose 4.7% after the half-year update, reflecting further NAV growth, strong cash realizations, and positive de-risking of its Pfizer obesity royalty exposure. Progress was broad-based, although the portfolio remains exposed to clinical, regulatory, and commercial risks.

Key Takeaways

• NAV per share increased approximately 3% to £1.14, taking NAV above £1 billion; NAV per share subsequently reached approximately £1.17 as of 11 September.
• Cash proceeds totaled £69 million in the first half—slightly above the full-year 2025 figure—with a further £17 million generated since June and gross cash of £239 million at period-end.
• The Pfizer obesity royalty interest rose £27 million to just over £150 million following positive berobenatide data and progression of the berobenatide/amylin combination into Phase IIb.
• Portfolio companies raised more than £500 million of third-party capital, with IP Group contributing approximately 5%, providing external validation of continued funding access.
• Pfizer is progressing 10 Phase III studies in 2026, with potential launch targeted for 2028; however, IP Group continues to apply probability-weighted valuation given clinical, regulatory, and commercial uncertainties.